Impending Flop for Brand Antiretrovirals in the Emerging Markets?
2008
Challenges for Brand Antiretrovirals in Emerging Markets
publication
Evidence: moderate
Author Information
Author(s): Daniele Dionisio, Daniela Messeri
Primary Institution: Pistoia Hospital, Italy
Hypothesis
Current trade policies for brand ARVs are at risk of failure in emerging markets.
Conclusion
Brand companies may need to adapt their strategies to remain competitive in emerging markets.
Supporting Evidence
- Generic companies are providing cheaper copies of brand ARVs in developing countries.
- Brand companies have pursued differential pricing and voluntary licenses with generic firms.
- Current trade policies may lead to a loss of market for brand ARVs in countries like India and Brazil.
Takeaway
This study looks at how brand-name HIV drugs might not do well in countries like India and Brazil because cheaper generic versions are available.
Potential Biases
Potential bias from the pharmaceutical industry may affect the findings.
Limitations
The study does not provide specific data on the effectiveness of brand versus generic ARVs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website